Vertex(US:VRTX)2025-08-04 20:30Financial Performance & Guidance - Q2 2025 total revenues reached $2.96 billion, compared to $2.65 billion in Q2 2024[48] - The company reiterated its 2025 total revenue guidance of $11.85-$12.0 billion[7] - Non-GAAP operating income for Q2 2025 was $1.33 billion, with a 45% operating margin[48] - Non-GAAP net income for Q2 2025 was $1.17 billion, or $4.52 per share diluted[48] - The company expects combined non-GAAP R&D, AIPR&D, and SG&A expenses to be $4.9-$5.0 billion for 2025[49] Key Product Updates - ALYFTREK generated $157 million in revenue in Q2 2025 and is approved for ages 6+ in the U S, U K, EU & Canada[33,48] - CASGEVY generated $30 million in revenue in Q2 2025, with 29 total patients infused since launch[40,48] - JOURNAVX generated $12 million in revenue in Q2 2025, with >110,000 prescriptions successfully filled as of mid-July[47,48] Pipeline Development - The company plans global regulatory submissions for Zimislecel (T1D) in 2026, targeting an initial launch to ~60,000 severe T1D patients[7,12] - Povetacicept (IgAN) Phase 3 interim analysis cohort is fully enrolled, with potential U S filing for accelerated approval in H1 2026[7,19] - VX-407 (ADPKD) Phase 2 proof-of-concept study is set to begin in Q3 2025, targeting up to ~30,000 patients with a subset of variants in the PKD1 gene[7,30]